Insider Edgemond Files to Sell United Therapeutics Shares

TL;DR

**Insider Edgemond is selling UTHR shares, watch out for potential stock dip.**

AI Summary

James Edgemond, a reporting person, has filed a Form 144 indicating a proposed sale of securities in United Therapeutics Corp (UTHR). This filing, dated March 23, 2026, signals that an insider intends to sell shares, which could be interpreted by investors as a lack of confidence in the company's future stock price. For current or prospective shareholders, this matters because significant insider selling can sometimes precede a decline in stock value, suggesting that those closest to the company believe the stock may be overvalued or that better opportunities exist elsewhere.

Why It Matters

This filing indicates a proposed sale of shares by an insider, James Edgemond, which could signal a lack of confidence in United Therapeutics Corp's future performance.

Risk Assessment

Risk Level: medium — Insider selling can sometimes precede a stock price decline, indicating that those with the most information about the company are cashing out.

Analyst Insight

A smart investor would monitor United Therapeutics Corp's stock performance closely and investigate the reasons behind James Edgemond's proposed sale, considering if it signals broader issues or simply personal financial planning.

Key Players & Entities

• EDGEMOND JAMES (person) — Reporting person proposing to sell securities
• UNITED THERAPEUTICS Corp (company) — Subject company whose securities are being proposed for sale
• 0001636178 (person) — CIK for EDGEMOND JAMES
• 0001082554 (company) — CIK for UNITED THERAPEUTICS Corp
• 2026-03-23 (date) — Filing Date and Accepted Date

Forward-Looking Statements

• The stock price of United Therapeutics Corp (UTHR) may experience downward pressure due to insider selling. (UNITED THERAPEUTICS Corp) — medium confidence, target: 2026-06-23

FAQ

Filing Documents

• primary_doc.html (144)
• primary_doc.xml (144) — 3KB
• 0001950047-26-002907.txt ( ) — 5KB

From the Filing

Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 FORM 144 144: Filer Information Is this a LIVE or TEST Filing? LIVE TEST Submission Contact Information Name Phone E-Mail Address 144: Issuer Information Name of Issuer United Therapeutics Corporation Address of Issuer 1000 SPRING ST SILVER SPRING MARYLAND 20910 Phone 3016089292 Name of Person for Whose Account the Securities are To Be Sold JAMES C EDGEMOND See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice. Relationship to Issuer Officer 144: Securities Information Title of the Class of Securities To Be Sold Name and Address of the Broker Number of Shares or Other Units To Be Sold Aggregate Market Value Number of Shares or Other Units Outstanding Approximate Date of Sale Name the Securities Exchange Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York � NY � 10004 120000 62913600.00 43827686 03/23/2026 NASDAQ Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor: 144: Securities To Be Sold Title of the Class Date you Acquired Nature of Acquisition Transaction Name of Person from Whom Acquired Is this a Gift? Date Donor Acquired Amount of Securities Acquired Date of Payment Nature of Payment * Common 03/23/2026 Exercise of Stock Options Issuer 120000 03/23/2026 Cash * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid. Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold. 144: Securities Sold During The Past 3 Months Nothing to Report 144: Remarks and Signature Remarks The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale. Date of Notice 03/23/2026 Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 10/31/2025 ATTENTION: The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature /s/ James C. Edgemond ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

View Full Filing

View this 144 filing on SEC EDGAR